The first and only FDA-approved topical gel for facial angiofibroma associated with tuberous sclerosis in adults and children 6 years and older
HYFTOR™ is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients 6 years of age and older. Facial angiofibroma is one of the most visible manifestations of TSC.1,2
HYFTOR is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.
CONTRAINDICATIONS
HYFTOR is contraindicated in patients with a history of hypersensitivity to sirolimus or any other component of HYFTOR.
WARNINGS AND PRECAUTIONS
ADVERSE REACTIONS
The most common adverse reactions (≥1%) are dry skin, application site irritation, pruritus, acne, acneiform dermatitis, ocular hyperemia, skin hemorrhage, and skin irritation.
USE IN SPECIFIC POPULATIONS
Please see full Prescribing Information for additional safety information.
© 2022 Nobelpharma America, LLC. All rights reserved.
HYF-PRO-1215-v1
This site is intended for U.S. healthcare professionals only.
HYFTOR is an mTOR inhibitor immunosuppressant indicated for the treatment of facial angiofibroma associated with tuberous sclerosis in adults and pediatric patients 6 years of age and older.
CONTRAINDICATIONS
HYFTOR is contraindicated in patients with a history of hypersensitivity to sirolimus or any other component of HYFTOR. READ MORE >>
By submitting your email address, you are opting in and may be provided with online advertisements or communications on Nobelpharma or third-party websites that are tailored to you, for example, on the basis of nonidentifying information or of your web browsing activity. When a Nobelpharma communication is delivered to you, you will see information about how to opt-out. By clicking the arrow, you agree and understand that your information will be governed by our Privacy Policy.
Link pending once FDA approval comes in…